Unsurprisingly, given these findings, RCC patients expressing high levels of DCLK1 showed poorer disease-specific (p < 0.05), progression-free (p < 0.05), and disease-free (p < 0.0001) survival (Figure 5D–F) in TCGA’s KIRC dataset. Here, DCLK1 is linked to renal cell carcinoma.